Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
Rev. Soc. Bras. Med. Trop
; Rev. Soc. Bras. Med. Trop;49(6): 774-776, Dec. 2016. graf
Article
de En
| LILACS
| ID: biblio-1041383
Bibliothèque responsable:
BR1.1
ABSTRACT
Abstract INTRODUCTION:
Intralesional treatment for cutaneous leishmaniasis has been applied for over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results and without relevant systemic toxicity. METHODS Meglumine antimoniate was injected subcutaneously, using a long medium-caliber needle (for example, 30mm × 0.8mm); patients received 1-3 injections, with 15-day intervals. RESULTS The technique is described in detail sufficient to enable replication.CONCLUSIONS:
The treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate is a simple, effective, and safe technique, which may be used in basic healthcare settings.Mots clés
Texte intégral:
1
Indice:
LILACS
Sujet Principal:
Composés organométalliques
/
Leishmaniose cutanée
/
Méglumine
/
Antiprotozoaires
Limites du sujet:
Humans
langue:
En
Texte intégral:
Rev. Soc. Bras. Med. Trop
Thème du journal:
MEDICINA TROPICAL
Année:
2016
Type:
Article